European Union’s mobilisation

The European Union is funding efforts to fight Ebola

EU humanitarian experts
- monitoring
- liaising with local authorities and partners

EBOLA in West Africa

Senegal  Mali  Guinea  Sierra Leone  Nigeria  Liberia  DRC

= Mobile lab
Ebola: the challenges

- Evolving epidemic
- No treatment/vaccines and no rapid diagnostics for use in the field
- Rapid scaling up of candidate vaccine doses needed is difficult;
- Current vaccine candidates require very cold temperatures for stability during transport;
- Deployment (reaching those most in need) is challenging;
- Adherence to vaccination regimens is challenging;
- Range of products needed for current and future outbreaks.
Industry response: beyond competition

* Engage with national health agencies

* Engage with national and international research funding organisations to accelerate R&D of products that can impact on the current epidemics

* Join forces across companies
  * Screening all companies portfolios to identify suitable antiviral candidates
  * Innovative Medicines Initiative

* Global coordination
EU Research funding mechanisms: 17 Ebola projects

✱ When?
✱ As soon as WHO rang the alarm bell

✱ What?
✱ Vaccines, Therapeutics, Diagnostics
✱ Basic research, Preparedness, Social sciences

✱ How?
✱ Horizon 2020
✱ Innovative Medicines Initiative
✱ Framework Programme 7
Innovative Medicines Initiative – Europe’s partnership for health

Neutral broker

Grants for public partners

In kind investment

Partnership 2008 - 2024

> €5 bn

€2.5 bn

€2.5 bn

European Union

EFPIA
Ebola+ programme overview
From Idea to Project start = 2-4 months !!

IMI2 Ebola and other filoviral haemorrhagic fevers programme
Joint Information repository, Scientific Advisory Board, Ethics Board

- Development
  - Topic 1: Vaccine development
    - Phase I, II, III
  - Topic 2: Stability during transport and storage
- Manufacturing
  - Topic 2: Manufacturing
- Deployment
  - Topic 4: Deployment & compliance with vaccination regimens
- Diagnostics
  - Topic 5: Rapid diagnostic tests
- Pipelines

VSV-EBOVAC
Sclavo Vacc. Assoc.

EBOMAN
Vibalogics, Janssen

EBODAC
LSHTM, Janssen

EBOVAC 1
LSHTM, Janssen

EBOVAC 2
Inserm, Janssen

EbolaMoDRAD
Public Health Institute Sweden

FILODIAG
GNA Biosolutions

Mofina
Public Health England, Altona

Total budget: € 215 million
Why the Innovative Medicines Initiative?

Collaboration between stakeholders and disciplines is a MUST to address the threat

Vaccinologists, infectious disease specialists, anthropologists, novel technologies, diagnostics, private industry

A neutral trusted platform facilitates exchange and helps align stakeholder’s interests
A concerted international effort

And many more...
Summary

- Massive, flexible and fast industry response

- International coordination and collaboration: avoiding overlaps, align with WHO steer

- Joining forces:
  - Across companies and sectors
  - Across public and private sectors
  - Across borders

- Continued effort – current and future epidemics